Aktienanalyse zu Alzamend Neuro Inc (ALZN)ALZNAlzamend Neuro Inc

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Alzamend Neuro Inc is a good buy right now, primarily due to its recent 5-day price increase of 16.45% and the positive sentiment from insider buying, where Milton C. Ault III purchased 108,388 shares at $1.00 each. The stock has regained Nasdaq compliance, indicating improved financial health, with stockholders' equity reported at $5.802 million, surpassing the minimum requirement of $2.5 million. However, the primary risk is the negative earnings trend, with a reported EPS of -0.68, which reflects ongoing losses.